The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis.
Helena Marzo-OrtegaVictoria Navarro-CompánServet AkarUta KiltzZoë ClarkElena NikiphorouPublished in: Clinical rheumatology (2022)
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic condition, historically considered a predominantly male disease. However, increasing evidence suggests a more equal prevalence between men and women. Of the limited research conducted to date, it is apparent that gender differences exist in terms of time to diagnosis, treatment outcomes and health-related quality of life (HRQoL). Despite this, women are underrepresented in clinical trials and most studies do not stratify by gender to identify potential differences in terms of disease manifestations and treatment response. In this perspectives article, we reflect on the potential biological and social factors contributing to these differences and propose three key areas of education and research that should be prioritised in order to address the unmet needs of female patients with axSpA, namely: (1) to identify ways to increase awareness of disease occurrence in female patients among healthcare professionals (HCPs), (2) to improve understanding of gender differences in disease manifestation and outcomes, and (3) to conduct gender-stratified clinical trials with a representative sample of female patients.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- mental health
- rheumatoid arthritis
- peritoneal dialysis
- risk assessment
- magnetic resonance imaging
- type diabetes
- systemic lupus erythematosus
- polycystic ovary syndrome
- climate change
- patient reported outcomes
- insulin resistance
- african american
- phase iii